Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Glaucoma Treatments Drive Business: Santen
May 30, 2011
- PIII Clinical Trial of Lu AA21004 for MDD Starts in Japan: Takeda
May 30, 2011
- Otsuka Announces 1st Midterm Management Plan
May 30, 2011
- BI, Eli Lilly Obtain Approval for Linagliptin in US
May 30, 2011
- Takara Bio Aims for Sales of \22.7 Bil. in FY2013
May 30, 2011
- Terumo Starts Domestic Clinical Study of Acetaminophen
May 30, 2011
- Mediceo: Yakkasa Reduction Rate of Just 0.5 Points in FY2010
May 30, 2011
- Sales Up 5.6% for Ethical Drugs in March Following Disaster: Crecon Research & Consulting
May 30, 2011
- Wholesale Business Deteriorating due to War for Market Share: Mr Hamada of Toho HD
May 30, 2011
- Teva to Acquire Majority Stake in Taiyo
May 30, 2011
- Premium for New Drug Development an “Incentive”to Japan Business: Chairman Viehbacher of PhRMA
May 30, 2011
- Teva-Taiyo Strategic Tie-up to Have “No Major Impact”on Sawai: President Sawai
May 30, 2011
- Astellas Completes Acquisition of Perseid
May 30, 2011
- Korosho Approves 2 Class 1 OTC Anti-allergic Eye Drops
May 30, 2011
- Daiichi Sankyo Launches SPRIX Nasal Spray in US
May 30, 2011
- Sanofi-aventis Changes Corporate Name to Sanofi
May 30, 2011
- NanoCarrier's NC-4016 to Obtain Substance Patent in US
May 30, 2011
- Operating Profits Down 60% Due to Stalled Price Negotiations: Suzuken
May 23, 2011
- Fingolimod Reduced Risk of MS Disability Progression: Novartis
May 23, 2011
- Operating Profits Drop 46.6% Due to Tough Price Negotiations: Toho HD
May 23, 2011
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…